Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) have been given a consensus recommendation of “Buy” by the six research firms that are presently covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $23.80.
Several equities research analysts have recently issued reports on LXEO shares. Chardan Capital raised their target price on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Leerink Partners dropped their target price on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Wednesday, November 13th. HC Wainwright increased their price target on Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, November 14th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $24.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday.
Check Out Our Latest Stock Report on LXEO
Lexeo Therapeutics Stock Up 14.5 %
Institutional Trading of Lexeo Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of LXEO. BNP Paribas Financial Markets increased its holdings in Lexeo Therapeutics by 184.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares during the period. Values First Advisors Inc. purchased a new position in shares of Lexeo Therapeutics during the third quarter valued at $67,000. SG Americas Securities LLC bought a new stake in shares of Lexeo Therapeutics in the fourth quarter valued at about $72,000. JPMorgan Chase & Co. lifted its stake in Lexeo Therapeutics by 135.6% in the third quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock worth $93,000 after acquiring an additional 5,915 shares during the period. Finally, MetLife Investment Management LLC grew its holdings in Lexeo Therapeutics by 121.5% during the 3rd quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock worth $129,000 after acquiring an additional 7,803 shares in the last quarter. Institutional investors own 60.67% of the company’s stock.
About Lexeo Therapeutics
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
Read More
- Five stocks we like better than Lexeo Therapeutics
- Most active stocks: Dollar volume vs share volume
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.